Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitrous Oxide in OCD
NCT03826693Phase 2
Key facts
- Status
- Recruiting
- Start
- Apr 2021
- Primary completion
- Sep 2026
- Countries
- 1
- Sponsor
- Stanford University
- Modality
- Small Molecules
- Drugs
- nitrous oxide
- Conditions
- obsessive compulsive disorder (OCD)
01
Overview
Phase 2, randomised, triple-blind trial of nitrous oxide in obsessive compulsive disorder (OCD) (2 arms), sponsored by Stanford University. Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 1 week. Started Apr 2021; status: recruiting.
02
Design
2 arms- Study design
- RandomizedTriple-blind
Nitrous Oxide Arm
Participants receive nitrous oxide in the first session and nitrogen in the second (or vice versa).
Nitrogen Arm
Participants receive nitrogen in the first session and nitrous oxide in the second (or vice versa).
03
Who it enrols
Adults aged 18-65 with a primary diagnosis of OCD of sufficient severity who are able to tolerate a treatment-free period.
04
Endpoints
Primary
Yale-Brown Obsessive Compulsive Scale
Beyond the preview
Go deeper on NCT03826693.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826693.